Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ALPS Group ( (ALPS) ) just unveiled an update.
On January 30, 2026, Alps Group Inc announced it is exploring an expansion of its exosome-related pipeline beyond its existing CELESOME(+) programme, prompted by the publication of a peer‑reviewed retrospective clinical case series on nebulized human umbilical cord mesenchymal stem cell-derived exosome therapy in patients with asthma and/or chronic obstructive pulmonary disease. The study, registered with Malaysia’s National Medical Research Register, reported preliminary observations of improved lung function, stable inflammatory markers and no significant adverse effects following a five‑week regimen of weekly inhaled exosome treatments via nebulizer, suggesting potential for a targeted, disease‑modifying approach in respiratory care and positioning the company to leverage its exosome expertise in a massive asthma and COPD market, while underscoring that larger, controlled trials are still needed before any regulatory or commercial outcomes can be expected.
More about ALPS Group
Alps Group Inc, based in Kuala Lumpur, is the parent of Alps Life Sciences Inc., an integrated biotechnology platform that combines research and development, medical services, and wellness solutions to deliver advanced therapies in predictive, preventive and precision medicine. The group’s stated mission is to build a fair healthcare ecosystem that makes cutting‑edge, individualized treatments more accessible and affordable worldwide.
Average Trading Volume: 390,272
Technical Sentiment Signal: Sell
Current Market Cap: $159.7M
For a thorough assessment of ALPS stock, go to TipRanks’ Stock Analysis page.